Literature DB >> 16810031

Home blood pressure in poorly controlled hypertension: relationship with ambulatory blood pressure and organ damage.

María A Martínez1, Teresa Sancho, Pilar García, Pilar Moreno, José M Rubio, Francisco J Palau, José L Antón, Francisco J Cirujano, José Sanz, Juan G Puig.   

Abstract

OBJECTIVES: (1) To assess whether home blood pressure measurement is a reliable alternative to ambulatory blood pressure monitoring for the evaluation of treated patients with inadequate blood pressure control at the clinic; and (2) to evaluate the relationship between home blood pressure and several target-organ damage markers. BASIC
METHODS: A cross-sectional study was performed in 225 treated hypertensive patients with persistently high blood pressure values at the clinic (systolic blood pressure 140 mmHg and/or diastolic blood pressure 90 mmHg). All study participants underwent clinic blood pressure measurement, 24-h ambulatory blood pressure and home blood pressure monitoring. A subgroup of patients underwent the following procedures: carotid echography (n=74), microalbuminuria determination (n=88) and echocardiography (n=43). We defined out-of-clinic normotension as an average ambulatory or home blood pressure less than 135 mmHg (systolic) and 85 mmHg (diastolic). MAIN
RESULTS: The sensitivity, specificity and positive and negative predictive values of the home blood pressure method for predicting out-of-clinic normotension (with the ambulatory method used as reference), expressed as percentages, were 50, 87, 64 and 79%, respectively. Systolic home blood pressure correlated significantly with left ventricular mass (r=0.33, P<0.05) and microalbuminuria (r=0.24, P<0.05). Similar correlation coefficients were found for systolic ambulatory blood pressure (r=0.32, P<0.05 and r=0.24, P<0.05, respectively). Clinic blood pressure did not correlate with either left ventricular mass or microalbuminuria (r=0.19, P=0.09 and r=0.19, P=0.24, respectively). Diastolic home blood pressure, but not ambulatory blood pressure, correlated negatively with mean carotid intima-media thickness (r=-0.27, P<0.05).
CONCLUSION: Our results suggest that, in patients with poorly controlled hypertension at the clinic, home blood pressure represents a complementary test rather than an alternative to ambulatory blood pressure, and correlates with several target-organ damage markers.

Entities:  

Mesh:

Year:  2006        PMID: 16810031     DOI: 10.1097/01.mbp.0000209073.30708.e1

Source DB:  PubMed          Journal:  Blood Press Monit        ISSN: 1359-5237            Impact factor:   1.444


  5 in total

Review 1.  Home blood pressure monitoring: primary role in hypertension management.

Authors:  George S Stergiou; Anastasios Kollias; Marilena Zeniodi; Nikos Karpettas; Angeliki Ntineri
Journal:  Curr Hypertens Rep       Date:  2014-08       Impact factor: 5.369

2.  Agreement between attended home and ambulatory blood pressure measurements in adolescents with chronic kidney disease.

Authors:  Trevor W Glenn; Cyd K Eaton; Kevin J Psoter; Michelle N Eakin; Cozumel S Pruette; Kristin A Riekert; Tammy M Brady
Journal:  Pediatr Nephrol       Date:  2022-02-15       Impact factor: 3.651

3.  Preventing misdiagnosis of ambulatory hypertension: algorithm using office and home blood pressures.

Authors:  Daichi Shimbo; Sujith Kuruvilla; Donald Haas; Thomas G Pickering; Joseph E Schwartz; William Gerin
Journal:  J Hypertens       Date:  2009-09       Impact factor: 4.844

4.  Hypertension with unsatisfactory sleep health (HUSH): study protocol for a randomized controlled trial.

Authors:  Jessica C Levenson; Bruce L Rollman; Lee M Ritterband; Patrick J Strollo; Kenneth J Smith; Jonathan G Yabes; Charity G Moore; Allison G Harvey; Daniel J Buysse
Journal:  Trials       Date:  2017-06-06       Impact factor: 2.279

5.  The disadvantage of morning blood pressure management in hypertensive patients.

Authors:  Kai Liu; Ying Xu; Shenzhen Gong; Jiangbo Li; Xinran Li; Runyu Ye; Hang Liao; Xiaoping Chen
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.